As the ‘Rona vaccine rolls out of deep freezers and toward a hospital near you, one man has bravely risked a 0.01% chance of death by courageously giving up his vaccine shot for you and grandma.
That man is Pfizer CEO Albert Bourla – just a charitable soul who has absolutely nothing to gain from being the first to get this vaccine to market.
When asked Monday if he had taken the vaccine, Bourla said no, explaining that there are bureaucratic rules to follow after all.
A health worker in Alaska had a serious allergic reaction after getting Pfizer Inc’s coronavirus vaccine, the New York Times reported on Wednesday, citing three people familiar with reports of the person’s health.The allergic reaction occurred on Tuesday and the person was in stable condition after being hospitalized, the New York Times reported.It was not clear if the person had a history of allergic reactions, the report said.
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run.
“Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.”
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”WATCH NOWVIDEO01:37Biotech shares soar on dealmaking, drug progress
Richter cited Gilead Sciences’ treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company’s U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.
“GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients,” the analyst wrote. “In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise.”
The analyst didn’t immediately respond to a request for comment.
The participant who triggered a global shutdown of AstraZeneca’s Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with a rare but serious spinal inflammatory disorder called transverse myelitis, the drug maker’s chief executive, Pascal Soriot, said during a private conference call with investors on Wednesday morning.
The woman’s diagnosis has not been confirmed yet, but she is improving and will likely be discharged from the hospital as early as Wednesday, Soriot said.
The board tasked with overseeing the data and safety components of the AstraZeneca clinical trials confirmed that the participant was injected with the company’s Covid-19 vaccine and not a placebo, Soriot said on the conference call, which was set up by the investment bank J.P. Morgan.
It should have already been considered a crime against humanity decades ago that law makers were lobbied (bribed) into passing legislation in which vaccine manufacturers cannot be held legally liable for any damage their products may cause. It was an act which established official protocols, such as the secret vaccine injury court to largely sweep under the rug any instances of such side effects.
But now a new lawsuit filed by the world’s largest vaccine manufacturer Serum Institute of India, in association with multinational pharmaceutical giant AstraZeneca, seeks to take this a step further — by attempting to set the precedent that vaccine manufacturers can actually sue those that may have been harmed by their faulty products.
The litigation filed in an Indian court is a countersuit to a lawsuit that has been filed against SII by one of the volunteers who participated in a trial study for the developmental Covisheild. A vaccination for SARS-CoV-2.
After participating in the trial study, the yet to be named volunteer flagged severe neurological and psychological symptoms 10 days after the first injection. Symptoms which were then diagnosed as acute neurological encephalopathy, resulting in memory loss, lapses in cognitive functions such as reasoning, and changes in personality. A legal notice had been sent to ICMR, DCGI, AstraZeneca and Oxford University to stop testing, manufacturing and distributing the vaccine. The plaintiff filed a suit after the notice failed to receive response.
SII then filed a countersuit, worth $13.5 million, for defamation after alleging that the volunteers illness had nothing to do with the vaccine trial. This is a statement which was also backed up by the Data and Safety Monitoring Board (DSMB) and DCGI (Drugs Controllor General of India). However, these assertions have been challenged by independent researcher Dr. Anant Bhan, the former President of the International Association of Bioethics and current professor at India’s Yenepoya Medical University. Dr. Bhan notes that both of these institutions are government entities directly affiliated with SII, and stresses that transparency should be the top priority given that the parties vested financial interests.
The imminent authorization of Pfizer’s Covid-19 vaccine in the United States is a momentous occasion for science, the economy and humanity. The milestone is also a major moneymaker for the companies that developed the vaccines.Wall Street analysts are projecting Pfizer and Moderna will generate $32 billion in Covid-19 vaccine revenue — next year alone.
Hellbound and Down 
You must be logged in to post a comment.